Press release
Niemann-Pick Type C Disease Pipeline Insight 2025: Targeted Therapies and Novel Mechanisms Aim to Halt Neurodegeneration | DelveInsight
The therapeutic pipeline for Niemann-Pick Type C (NPC) disease is advancing to address the urgent need to slow its progressive neurological decline. Current treatments like miglustat delay symptoms but don't target underlying cholesterol and lipid trafficking defects, highlighting the need for disease-modifying therapies to improve survival and quality of life.DelveInsight's "Niemann-Pick Type C Disease - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights an emerging portfolio of candidates targeting multiple disease pathways-ranging from small molecules that restore lipid homeostasis to gene therapies designed to correct NPC1/NPC2 mutations. Cyclodextrin-based agents, histone deacetylase (HDAC) inhibitors, and oxysterol derivatives are in advanced stages of development, aiming to enhance cholesterol clearance and reduce neuroinflammation. Novel approaches such as intrathecal delivery of 2-hydroxypropyl--cyclodextrin (HPCD), ASOs targeting NPC gene expression, and adeno-associated virus (AAV)-mediated gene replacement are showing promise in clinical and preclinical studies.
The 2025 pipeline reflects a strategic shift from symptomatic management to precision interventions that directly address NPC pathophysiology. Growing regulatory support for rare disease innovation, coupled with international patient registry data, is accelerating trial design and recruitment. With advances in targeted small molecules, RNA-based therapeutics, and gene therapy platforms, the coming years may redefine the standard of care for Niemann-Pick Type C, offering renewed hope to patients and families facing this devastating condition.
Interested in learning more about the current treatment landscape and the key drivers shaping the Niemann-Pick Type C Disease pipeline? Click here [https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Key Takeaways from the Niemann-Pick Type C Disease Pipeline Report
- DelveInsight's Niemann-Pick Type C Disease pipeline analysis depicts a strong space with 3+ active players working to develop 5+ pipeline drugs for Niemann-Pick Type C Disease treatment.
- The leading Niemann-Pick Type C Disease companies include Zevra Therapeutics, Azafaros, Cyclo Therapeutics, IntraBio, SOM Biotech, ENDECE, and others are evaluating their lead assets to improve the Niemann-Pick Type C Disease treatment landscape.
- Key Niemann-Pick Type C Disease pipeline therapies in various stages of development include Arimoclomol, AZ 3102, Trappsol Cyclo, IB1001, SOM-0208, NDC 1308, and others.
- In April 2025, a peer-reviewed update summarized these 2024 approvals and their implications for clinical practice and ongoing trials in NPC.
- In September 2024, the FDA also approved arimoclomol (Miplyffa) for NPC, providing another treatment option for this lysosomal storage disorder.
- In September 2024, the FDA approved levacetylleucine (Aqneursa) as the first disease-modifying therapy for NPC, based on IB1001 data.
Niemann-Pick Type C Disease Overview
Niemann-Pick Type C (NPC) disease is a rare, inherited neurodegenerative disorder characterized by the body's inability to properly metabolize cholesterol and other lipids within cells. This leads to the accumulation of toxic substances in various organs, including the brain, liver, and spleen, causing progressive neurological decline, liver dysfunction, and respiratory issues. Symptoms typically appear in infancy or childhood but can manifest at any age, and include difficulties with movement, learning disabilities, seizures, and psychiatric problems.
NPC is caused by mutations in the NPC1 or NPC2 genes, which play critical roles in lipid transport within cells. Currently, there is no cure for the disease, but treatments focus on managing symptoms and slowing disease progression. Research and clinical trials are ongoing to develop therapies that can improve outcomes for affected individuals, including the use of drugs aimed at reducing lipid accumulation or enhancing cellular function.
Find out more about Niemann-Pick Type C Disease medication at https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight [https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Niemann-Pick Type C Disease Treatment Analysis: Drug Profile
Trappsol Cyclo: Cyclo Therapeutics, Inc.
Trappsol Cyclo, developed by Cyclo Therapeutics, Inc., is a proprietary formulation of hydroxypropyl beta cyclodextrin that has demonstrated promising results in multiple clinical studies for managing cholesterol transport. Acting as a substitute for the defective NPC1 protein, its cyclic structure helps transport accumulated cholesterol out of cellular lysosomes, allowing it to be processed and eliminated from the cells. Trappsol Cyclo is currently undergoing clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC), a rare, progressive, and fatal genetic disorder, as well as Alzheimer's disease, a progressive neurological condition in which elevated cholesterol is also a known risk factor. The drug has received FDA Fast Track Designation for NPC treatment and has been granted Orphan Drug status by both the FDA and the European Medicines Agency. It is presently in Phase III clinical development for Niemann-Pick Type C Disease.
Learn more about the novel and emerging Niemann-Pick Type C Disease pipeline therapies [https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].
Niemann-Pick Type C Disease Therapeutics Assessment
By Product Type
- Mono
- Combination
- Mono/Combination.
By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
By Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
By Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Scope of the Niemann-Pick Type C Disease Pipeline Report
- Coverage: Global
- Key Niemann-Pick Type C Disease Companies: Zevra Therapeutics, Azafaros, Cyclo Therapeutics, IntraBio, SOM Biotech, ENDECE, and others.
- Key Niemann-Pick Type C Disease Pipeline Therapies: Arimoclomol, AZ 3102, Trappsol Cyclo, IB1001, SOM-0208, NDC 1308, and others.
Explore detailed insights on drugs used in the treatment of Niemann-Pick Type C Disease here [https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].
Table of Contents
1. Introduction
2. Executive Summary
3. Niemann-Pick Type C Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Niemann-Pick Type C Disease Pipeline Therapeutics
6. Niemann-Pick Type C Disease Pipeline: Late-Stage Products (Phase III)
7. Niemann-Pick Type C Disease Pipeline: Mid-Stage Products (Phase II)
8. Niemann-Pick Type C Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=niemannpick-type-c-disease-pipeline-insight-2025-targeted-therapies-and-novel-mechanisms-aim-to-halt-neurodegeneration-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Niemann-Pick Type C Disease Pipeline Insight 2025: Targeted Therapies and Novel Mechanisms Aim to Halt Neurodegeneration | DelveInsight here
News-ID: 4146401 • Views: …
More Releases from ABNewswire

DMB Plumbing & Heating Urges Homeowners to Schedule Pre-Winter Heating Inspectio …
DMB Plumbing & Heating Inc. of Bridgewater, led by Dean Blanchard, is urging homeowners to schedule pre-winter heating inspections.
As temperatures in Massachusetts begin to dip and residents prepare their homes for another New England winter, DMB Plumbing & Heating Inc., a locally owned and operated company based in Bridgewater, is reminding homeowners of the importance of pre-winter heating inspections.
Founded and operated by Dean Blanchard, DMB Plumbing & Heating has long…

BitX Capital Champions Merchant Cash Advance as a Flexible Funding Alternative f …
About BitX Capital: Founded in 2013, BitX Capital specializes in connecting small and medium-sized businesses with customized funding solutions. Leveraging deep market knowledge and led by a veteran team, BitX Capital simplifies the complex world of business lending, empowering businesses with the capital needed for growth and stability.
October 9, 2025 - BitX Capital, a trusted leader in small business financing, today announcement underscored the value of the Merchant Cash Advance…

Cell and Gene Therapy in Parkinson's Disease Market to Experience Notable Growth …
The Key Cell and Gene Therapy in Parkinson's Disease Companies in the market include - Prevail Therapeutics (Eli Lilly), MeiraGTx, Hope Biosciences, and others.
DelveInsight's "Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Cell and Gene Therapy in Parkinson's Disease, historical and forecasted epidemiology as well as the Cell and Gene Therapy in Parkinson's Disease market trends in the…

Polycythemia Vera Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Polycythemia Vera pipeline constitutes 8+ key companies continuously working towards developing 10+ Polycythemia Vera treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Polycythemia Vera Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Type
Pressure Pumping Market 2028 By Type, Well Type, Resource Type and Geography
The Insight Partners delivers well-researched industry-wide information on the Pressure Pumping market. It provides information on the market's essential aspects such as top participants, factors driving Pressure Pumping market growth, precise estimation of the Pressure Pumping market size, upcoming trends, changes in consumer behavioral pattern, market's competitive landscape, key market vendors, and other market features to gain an in-depth analysis of the market. Additionally, the report is a compilation of…
Lawn Mowers Market Analysis By Type, End User, Product Type, Fuel Type, Engine P …
Lawn Mowers Market Analysis By Type(Manual, Electric, Petrol, Robotic), By End User(Residential, Commercial), By Product Type(Walk behind Movers, Ride on Movers, Stand on Movers), By Fuel Type(Gas Powered, Propane Powered), By Engine Power(Less than 15 hp, Between 15hp and 30 hp, More than 30 hp), By Blade Type(Cylinder, Standard, Mulching, Lifting), By Drive Type(AWD, FWD, RWD), By Application(Residential, Professional landscaping, Golf Course, Government), By Distribution Channel(Retail Store, Online Website) &…
Automotive Exhaust System Component Market Type, Fuel Type, Treatment Device, Ve …
Automotive Exhaust System Component Market
This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering
Tenneco
Faurecia
Eberspacher
Boysen
Sango
HITER
Yutaka Giken
Calsonic Kansei
Magneti Marelli
Benteler
Sejong Industrial
Katcon
Futaba
Wanxiang
Bosal
Harbin Airui
Dinex
Catar
DSM
Get Sample PDF including full TOC, Tables and Figures @ https://www.ozonemarketreports.com/automotive-and-transportation/global-automotive-exhaust-system-components-market-professional-survey-report-2019/59563
On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
Exhaust Manifold
Exhaust Pipe
Catalytic Converter
Exhaust Temperature Sensor
Car Muffler
Exhaust…
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Automotive Electric Vacuum Pump Market By Type Diaphragm Type, Swing Piston Type …
Automatic electric vacuum pump is a device that gets the drive from the camshaft in the engine. It can also be run by alternator shaft in some designs. It’s an added benefit to any engine, which has high performance. The primary function of an automatic electric vacuum pump is to drain out the air from brake booster tank hence creating the vacuum, which in turn can be used for application…
Marine Composites Market |By Type |Resin Type|Vessel Type|Fiber Type |Region Ana …
The report includes market segmentation by composites type (metal matrix composite, ceramic matrix composite, polymer matrix composite); polymer matrix composite by fiber type (glass fiber, carbon fiber, others); polymer matrix composite by resin type (polyester, vinyl ester, epoxy, thermoplastic, others); vessel type (power boats, sailboats, cruise ships, others); and region (North America, Europe, APAC, Latin America, MEA).
Download Latest Free PDF Sample Brochure of “Marine Composites Market” With Detailed TOC…